NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.7460 -0.01 (-1.32 %) (As of 07/20/2018 04:00 PM ET)Previous Close$0.7460Today's Range$0.7450 - $0.7952-Week Range$0.74 - $3.78Volume819,260 shsAverage Volume990,356 shsMarket Capitalization$21.82 millionP/E Ratio-0.59Dividend YieldN/ABeta0.79 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts. Receive CATB News and Ratings via Email Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:CATB CUSIPN/A Webwww.catabasis.com Phone617-349-1971 Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio3.40 Price-To-Earnings Trailing P/E Ratio-0.59 Forward P/E Ratio-0.72 P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales43.31 Cash FlowN/A Price / CashN/A Book Value$0.51 per share Price / Book1.46 Profitability EPS (Most Recent Fiscal Year)($1.26) Net Income$-27,360,000.00 Net MarginsN/A Return on Equity-175.32% Return on Assets-120.22% Miscellaneous Employees36 Outstanding Shares29,030,000Market Cap$21.82 Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions What is Catabasis Pharmaceuticals' stock symbol? Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB." How were Catabasis Pharmaceuticals' earnings last quarter? Catabasis Pharmaceuticals Inc (NASDAQ:CATB) issued its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.06. View Catabasis Pharmaceuticals' Earnings History. When is Catabasis Pharmaceuticals' next earnings date? Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Catabasis Pharmaceuticals. What price target have analysts set for CATB? 6 equities research analysts have issued 12-month target prices for Catabasis Pharmaceuticals' stock. Their predictions range from $2.00 to $9.00. On average, they expect Catabasis Pharmaceuticals' stock price to reach $5.6667 in the next twelve months. This suggests a possible upside of 659.6% from the stock's current price. View Analyst Ratings for Catabasis Pharmaceuticals. What is the consensus analysts' recommendation for Catabasis Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Catabasis Pharmaceuticals? Catabasis Pharmaceuticals saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 1,041,157 shares, an increase of 66.8% from the May 31st total of 624,147 shares. Based on an average daily trading volume, of 290,944 shares, the days-to-cover ratio is currently 3.6 days. Currently, 4.9% of the shares of the company are sold short. View Catabasis Pharmaceuticals' Current Options Chain. Who are some of Catabasis Pharmaceuticals' key competitors? Some companies that are related to Catabasis Pharmaceuticals include SCYNEXIS (SCYX), Checkpoint Therapeutics (CKPT), Scpharmaceuticals (SCPH), Elite Pharmaceuticals, Inc. Common Stock (ELTP), DiaMedica Therapeutics (DMCAF), Sunesis Pharmaceuticals (SNSS), Medicure Inc. Common Stock (MCUJF), Cardiome Pharma (CRME), Neurotrope (NTRP), Axsome Therapeutics (AXSM), Vernalis (VNLPY), VIVUS (VVUS), Trillium Therapeutics (TRIL), Novan (NOVN) and Advaxis (ADXS). Who are Catabasis Pharmaceuticals' key executives? Catabasis Pharmaceuticals' management team includes the folowing people: Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 50)Dr. Andrew J. Nichols, Chief Scientific Officer (Age 57)Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 61)Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 53)Dr. Angelika Fretzen Ph.D., Sr. VP of Product Devel. When did Catabasis Pharmaceuticals IPO? (CATB) raised $60 million in an IPO on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers. Has Catabasis Pharmaceuticals been receiving favorable news coverage? News stories about CATB stock have been trending somewhat negative this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a coverage optimism score of 0.00 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.97 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. How do I buy shares of Catabasis Pharmaceuticals? Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Catabasis Pharmaceuticals' stock price today? One share of CATB stock can currently be purchased for approximately $0.7460. How big of a company is Catabasis Pharmaceuticals? Catabasis Pharmaceuticals has a market capitalization of $21.82 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-27,360,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Catabasis Pharmaceuticals employs 36 workers across the globe. How can I contact Catabasis Pharmaceuticals? Catabasis Pharmaceuticals' mailing address is One Kendall SquareBldg. 1400E SuiteB14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected] MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 225 (Vote Outperform)Underperform Votes: 129 (Vote Underperform)Total Votes: 354MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?